Back to Search Start Over

Cranial nerve palsies and intracranial aneurysms: A narrative review of patterns and outcomes.

Authors :
Hoz SS
Ma L
Muthana A
Al-Zaidy MF
Ahmed FO
Ismail M
Jacobs RC
Agarwal P
Al-Bayati AR
Nogueira RG
Lang MJ
Gross BA
Source :
Surgical neurology international [Surg Neurol Int] 2024 Aug 09; Vol. 15, pp. 277. Date of Electronic Publication: 2024 Aug 09 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: Cranial nerve palsy (CNP) in patients with intracranial aneurysms (IAs) can impose significant burdens on a patient's quality of life. The literature has a paucity of reviews addressing patterns of overall reported cranial nerve (CN) involvement and outcomes in patients with IA.<br />Methods: The literature systematically reviewed CNP at presentation in the setting of IA using PubMed, Web-of-Science, and Scopus according to the PRISMA guidelines.<br />Results: Fifty-two studies reported a total of 513 patients with IA and 630 CNPs observed at presentation: oculomotor (58.25%), abducent (15.87%), optic (12.06%), trochlear (8.7%), and trigeminal (1.9%). Most common aneurysms are located in a posterior communicating artery (46%) and cavernous internal carotid artery (29.2%). Trends of CNP based on the rupture status of IAs showed that 80% were associated with unruptured IAs and 20% with ruptured IAs. Post-treatment of IA, 55% of patients had complete resolution of CNP, with most (89%; n = 134) resolving within the first 6 months. Stratified by CNP type: Complete resolution rate is 100% in CN VII-IX, 60% in CN VI, 59% in CN IV, 54% in CN III, 45% in CN V, and 43% in CN II.<br />Conclusion: In patients with cranial nerve palsies attributed to IAs, the location and rupture status of the aneurysm could determine the type and severity of the nerve palsy. Most patients experienced favorable outcomes in terms of their resolution and long-term function of the CNP after treatment of the IA.<br />Competing Interests: Dr. Gross is a consultant for Medtronic, Stryker, and MicroVention. Dr. Nogueira reports consulting fees for advisory roles with Stryker Neurovascular, Cerenovus, Medtronic, Phenox, Anaconda, Genentech, Biogen, Prolong Pharmaceuticals, Imperative Care and stock options for advisory roles with Brainomix, Viz-AI, Corindus Vascular Robotics, Vesalio, Ceretrieve, Astrocyte, and Cerebrotech.<br /> (Copyright: © 2024 Surgical Neurology International.)

Details

Language :
English
ISSN :
2229-5097
Volume :
15
Database :
MEDLINE
Journal :
Surgical neurology international
Publication Type :
Academic Journal
Accession number :
39246770
Full Text :
https://doi.org/10.25259/SNI_531_2024